---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016832"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:13:08.513695+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma Q3 FY2025 net income $4M, revenue up 32% YoY to $18.5M

## Summary
- Net income of $4.0M ($0.65 basic / $0.21 diluted EPS) vs net loss of $2.9M a year ago.
- Total net revenue $18.5M, up 32% YoY; ADHD portfolio up 25% to $15.4M, Pediatric up 77% to $3.1M.
- Adjusted EBITDA $3.9M vs $0.9M in Q3 FY2024; operating expenses down 13% YoY.
- Cash $18.2M at March 31, 2025; paid down $2.5M in long-term debt during the quarter.
- Gross margin 69% vs 74% prior year due to higher-cost ADHD inventory from closed Texas facility; expected to normalize.

## SEC filing metadata
- accession: 0001437749-25-016832
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774925016832/0001437749-25-016832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774925016832/aytu20250213_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016832
- JSON: https://secwatch.observer/filing/0001437749-25-016832.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.